Inhibition of complement C3 might rescue vascular hyporeactivity in a conscious hemorrhagic shock rat model

Microvascular Research

Volumn 105, Issue , 2016, Pages 23-29

  Chen, Ding ^a   Song, Meng Qi ^a   Liu, Yan Jun ^a   Xue, Yin Kai ^a   Cheng, Ping ^a   Zheng, Hai ^a   Chen, Li Bo ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Complement; Hemorrhagic shock; Vascular reactivity

Indexed keywords

COBROTOXIN; COMPLEMENT COMPONENT C3; ENDOTHELIN 1; NITRIC OXIDE; NORADRENALIN; REACTIVE OXYGEN METABOLITE; SOLUBLE COMPLEMENT RECEPTOR 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT INHIBITOR; SNAKE VENOM; TUMOR NECROSIS FACTOR; VASOCONSTRICTOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL REACTIVITY; CONSCIOUSNESS; CONTROLLED STUDY; HEMORRHAGIC SHOCK; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; RAT MODEL; SUPERIOR MESENTERIC ARTERY; VASCULAR HYPOREACTIVITY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLEMENT ACTIVATION; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; SHOCK, HEMORRHAGIC; SPRAGUE DAWLEY RAT; TIME FACTOR; VASOCONSTRICTION;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT INACTIVATING AGENTS; DISEASE MODELS, ANIMAL; ELAPID VENOMS; ENDOTHELIN-1; MESENTERIC ARTERY, SUPERIOR; NITRIC OXIDE; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTORS, COMPLEMENT 3B; SHOCK, HEMORRHAGIC; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 84960844443     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2015.12.006     Document Type: Article

References (50)

1. Alexander J.J., Anderson A.J., Barnum S.R., Stevens B., Tenner A.J. The complement cascade. Yin-yang in neuroinflammation-neuro-protection and -degeneration. J. Neurochem. 2008, 107:1169-1187.
2. Alvarez S., Boveris A. Mitochondrial nitric oxide metabolism in rat muscle during endotoxemia. Free Radic. Biol. Med. 2004, 37:1472-1478.
3. Barrett L.K., Orie N.N., Taylor V., Stidwill R.P., Clapp L.H., Singer M. Differential effects of vasopressin and norepinephrine on vascular reactivity in a long-term rodent model of sepsis. Crit. Care Med. 2007, 35:2337-2343.
4. Barrett L.K., Orie N.N., Taylor V., et al. Differential effects of vasopressin and norepinephrine on vascular reactivity in a long-term rodent model of sepsis. Crit. Care Med. 2007, 35(10):2337-2343.
5. Barrett T.D., Hennan J.K., Marks R.M., Lucchesi B.R. C-reactive-proteinassociated increase in myocardial infarct size after ischemia/reperfusion. J. Pharmacol. Exp. 2002, 303:1007-1013.
6. Becker L.B. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc. Res. 2004, 61:461-470.
7. Boffa J.J., Arendshorst W.J. Maintenance of renal vascular reactivity contributes to acute renal failure during endotoxemic shock. J. Am. Soc. Nephrol. 2005, 16:117-124.
8. Cauwels A. Nitric oxide in shock. Kidney Int. 2007, 72:557-565.
9. Cauwels A., Brouckaert P. Critical role for small and large conductance calcium-dependent potassium channels in endotoxemia and TNF toxicity. Shock 2008, 29:577-582.
10. Curzen N.P., Kaddoura S., Griffiths M.J., Evans T.W. Endothelin-1 in rat endotoxemia: mRNA expression and vasoreactivity in pulmonary and systemic circulations. Am. J. Physiol. Heart Circ. Physiol. 1997, 272:H2353-H2360.
11. Diepenhorst G.M., van Gulik T.M., Hack C.E. Complement-mediated ischemia-reperfusion injury: lessons learned from animal and clinical studies. Ann. Surg. 2009, 249:889-899.
12. Fleming S.D., Shea-Donohue T., Guthridge J.M., Kulik L., Waldschmidt T.J., Gipson M.G., Tsokos G.C., Holers V.M. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J. Immunol. 2002, 169:2126-2133.
13. Giustarini D., Tsikas D., Rossi R. Study of the effect of thiols on the vasodilatory potency of S-nitrosothiols by using a modified aortic ring assay. Toxicol. Appl. Pharmacol. 2011, 256:95-102.
14. Goodfellow R.M., Williams A.S., Levin J.L., Williams B.D., Morgan B.P. Soluble complement receptor one (SCR1) inhibits the development and progression of rat collagen-induced arthritis. Clin. Exp. Immunol. 2000, 119:210-216.
15. Guc M.O., Furman B.L., Parratt J.R. Endotoxin-induced impairment of vasopressor and vasodepressor responses in the pithed rat. Br. J. Pharmacol. 1990, 101:913-919.
16. Hecke F., Hoehn T., Srauss E., Obladen M., Sonntag J. In vitro activation of complement system by lactic acidosis in newborn adults. Mediat. Inflamm. 2001, 10:27-31.
17. Hecke F., Schmidt U., Kola A., Bautsch W., Klos A., Köhl J. Circulating complement proteins in multiple trauma patients: correlation with injury severity, development of sepsis, and outcome. Crit. Care Med. 1997, 25:2015-2024.
18. Jordan J.E., Montalto M.C., Stahl G.L. Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 2001, 104:1413-1418.
19. + channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. J. Clin. Invest. 1992, 89:2071-2074.
20. Lange M., Morelli A., Ertmer C., Bröking K., Rehberg S., Van Aken H., et al. Role of adenosine triphosphate-sensitive potassium channel inhibition in shock states: physiology and clinical implications. Shock 2007, 28:394-400.
21. Lehmann T.G., Koeppel T.A., Kirschfink M., Gebhard M.M., Herfarth C., Otto G., Post S. Complement inhibition by soluble complement receptor type 1 improves microcirculation after rat liver transplantation. Transplantation 1998, 66:717-722.
22. Levy B., Valtier M., de Chillou C., Bollaert P.E., Cane D., Mallie J.P. Beneficial effects of l-canavanine, a selective inhibitor of inducible nitric oxide synthase, on lactate metabolism and muscle high energy phosphates during endotoxic shock in rats. Shock 1999, 11:98-103.
23. Liu L.-m., Dubick M.A. Hemorrhagic shock-induced vascular hyporeactivity in the rat. Relationship to gene expression of nitric oxide synthase, endothelin-1, and select cytokines in corresponding organs. J. Surg. Res. 2005, 125:128-136.
24. Lundberg J.O., Weitzberg E. NO generation from nitrite and its role in vascular control. Arterioscler. Thromb. Vasc. Biol. 2005, 25:915-922. (pathway).
25. Mocco J. Preclinical evaluation of the neuroprotective effect of soluble complement receptor type 1 in a nonhuman primate model of reperfused stroke. J. Neurosurg. 2006, 105:595-601.
26. Morgan B.P., Harris C.L. Complement therapeutics; history and current progress. Mol. Immunol. 2003, 40:159-170.
27. Nathan C., Xie Q.W. Nitric oxide synthases: roles, tolls, and controls. Cell 1994, 78(6):915-918. (Sep 23).
28. + channels. Am. J. Physiol. 2005, 289(5):2244-2250.
29. Pacher P., Beckman J.S., Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 2007, 87:315-424.
30. Peitzman A.B., Billiar T.R., Harbrecht B.G., Kelly E., Udekwu A.O., Simmons R.L. Hemorrhagic shock. Curr. Probl. Surg. 1995, 32:925-1002.
31. Price R.R., Morris D.P., Biswas G., Smith M.P., Schwinn D.A. Acute agonist-mediated desensitization of the human 1a-adrenergic receptor is primarily independent of carboxyl terminus regulation. J. Biol. Chem. 2002, 277(11):9570-9579.
32. Pruitt S.K., Bollinger R.R. The effect of soluble complement receptor type 1 on hyperacute allograft rejection. J. Surg. Res. 1991, 50:350-355.
33. Quigg R.J. Use of complement inhibitors in tissue injury. Trends Mol. Med. 2002, 8(9):430-436. (Sep).
34. Shah K.J., Chiu W.C., Scalea T.M., Carlson D.E. Detrimental effects of rapid fluid resuscitation on hepatocellular function and survival after hemorrhagic shock. Shock 2002, 18(3):242-247.
35. Shandelya S.M., Kuppusamy P., Herskowitz A., Weisfeldt M.L., Zweier J.L. Soluble complement receptor type 1 inhibits the complement pathway and prevents contractile failure in the postischemic heart. Evidence that complement activation is required for neutrophil-mediated reperfusion injury. Circulation 1993, 88:2812-2826.
36. Szebeni J., Baranyi B., Savay S., Bodo M., Morse D.S., Basta M., Stahl G.L., Bunger R., Alving C.R. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am. J. Physiol. 2000, 279:H1319-H1328.
37. Szebeni J., Baranyi L., Savay S., Götze O., Alving C.R., Bünger R., Mongan P.D. Complement activation during hemorrhagic shock and resuscitation in swine. Shock 2003, 20(4):347-355.
38. Szebeni J., Fontana J.L., Wassef N.M., Mongan P.D., Morse D.S., Dobbins D.E., Stahl G.L., Bünger R., Alving C.R. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudo-allergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 1999, 99:2302-2309.
39. Umans J.G., Wylam M.E., Samsel R.W., Edwards J., Schumacker P.T. Effects of endotoxin in vivo on endothelial and smooth-muscle function in rabbit and rat aorta. Am. Rev. Respir. Dis. 1993, 148:1638-1645.
40. Vermeulen N.P.E., Baldew G.S. The role of lipid peroxidation in the nephrotoxicity of cisplatin. Biochem. Pharmacol. 1992, 44:1193-1199.
41. Vogel C.W., Fritzinger D.C. Cobra venom factor: structure, function, and humanization for therapeutic complement depletion. Toxicon 2010, 56:1198-1222.
42. Vogel C.W., Müller-Eberhard H.J. Cobra venom factor: improved method for purification and biochemical characterization. J. Immunol. Methods 1984, 73:203-220.
43. Wahl S.M., Arend W.P., Ross R. The effect of complement depletion of wound healing. Am. J. Pathol. 1974, 75(1):73-90.
44. Walker T.A., Curtis S.E., King-VanVlack C.E., Chapler C.K., Vallet B., Cain S.M. Effects of nitric oxide synthase inhibition on regional hemodynamics and oxygen transport in endotoxic dogs. Shock 1995, 4:415-420.
45. Watts J.A., Kline J.A. Bench to bedside: the role of mitochondrial medicine in the pathogenesis and treatment of cellular injury. Acad. Emerg. Med. 2003, 10:985-997.
46. Weisman H.F., Bartow T., Leppo M.K., et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990, 249:146-151.
47. Williams J.P., Pechet T.T., Weiser M.R., Reid R., Kobzik L., Moore F.D., Carroll M.C., Hechtman H.B. Intestinal reperfusion injury is mediated by IgM and complement. J. Appl. Physiol. 1999, 86:938-942.
48. Yang S., Nakamura T., Hua Y., Keep R.F., Younger J.G., He Y., Hoff J.T., Xi G. The role of complement C3 in intracerebral hemorrhage-induced brain injury. J. Cereb. Blood Flow Metab. 2006, 26:1490-1495.
49. Zimmerman J.L., Dellinger R.P., Straube R.C., Levin J.L. Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit. Care Med. 2000, 28:3149-3154.
50. Zweifach B.W., Thomas L. The relationship between the vascular manifestations of shock produced by endotoxin, trauma, and hemorrhage. I. Certain similarities between the reactions in normal and endotoxin-tolerant rats. J. Exp. Med. 1957, 106:385-401.